Market capitalization | $38.27m |
Enterprise Value | $-46.33m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.39 |
P/B ratio (TTM) P/B ratio | 0.23 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-44.25m |
Free Cash Flow (TTM) Free Cash Flow | $-33.42m |
Cash position | $89.58m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Protara Therapeutics Inc forecast:
4 Analysts have issued a Protara Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.38 -0.38 |
41%
41%
|
|
EBITDA | -44 -44 |
12%
12%
|
EBIT (Operating Income) EBIT | -44 -44 |
11%
11%
|
Net Profit | -41 -41 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.
Head office | United States |
CEO | Jesse Shefferman |
Employees | 27 |
Founded | 2006 |
Website | www.protaratx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.